RxDoctor Payments Data

Andrew Bullock, MD

Urology · Greenville, SCNPI 1194936385

Payments from drug & device makers

$1,849in general payments, 2019–2025

Across 104 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$805
  • Bioprotect Medical, Inc.$135
  • AbbVie$125
  • Boston Scientific$107
  • Progenics Pharmaceuticals, Inc.$105
  • Astellas Pharma US Inc$88
  • plus $483 from 15 others

What the payments were for

  • Food & beverage$1,849100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,849 in reported general payments places this provider in the 35th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$221,931
Medicare patients
888
Services billed
8,752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron57$47,110
GemtesaVibegron18$19,407
Finasteride1,593$19,208
Tamsulosin Hcl1,090$13,779
Silodosin65$7,639
Tolterodine Tartrate ErTolterodine Tartrate18$7,170
Potassium Citrate ErPotassium Citrate30$3,259
Testosterone25$3,248
Dutasteride70$2,653
NitrofurantoinNitrofurantoin Macrocrystal32$857
Oxybutynin Chloride63$848
Alfuzosin Hcl ErAlfuzosin Hcl43$762
Solifenacin Succinate19$580
Testosterone Cypionate26$488
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim80$404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$88$47,11057 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 196 urology providers in South Carolina.

Other urology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →